Your browser doesn't support javascript.
loading
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.
Michielin, O; van Akkooi, A; Lorigan, P; Ascierto, P A; Dummer, R; Robert, C; Arance, A; Blank, C U; Chiarion Sileni, V; Donia, M; Faries, M B; Gaudy-Marqueste, C; Gogas, H; Grob, J J; Guckenberger, M; Haanen, J; Hayes, A J; Hoeller, C; Lebbé, C; Lugowska, I; Mandalà, M; Márquez-Rodas, I; Nathan, P; Neyns, B; Olofsson Bagge, R; Puig, S; Rutkowski, P; Schilling, B; Sondak, V K; Tawbi, H; Testori, A; Keilholz, U.
Afiliação
  • Michielin O; Department of Oncology, University Hospital Lausanne, Lausanne, Switzerland. Electronic address: clinicalguidelines@esmo.org.
  • van Akkooi A; Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Lorigan P; Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
  • Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Dummer R; Department of Dermatology, University Hospital Zürich, Zürich, Switzerland.
  • Robert C; Department of Medicine, Gustave Roussy, Villejuif, France; Paris-Saclay University, Le Kremlin-Bicêtre, Paris, France.
  • Arance A; Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Blank CU; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Chiarion Sileni V; Department of Experimental and Clinical Oncology, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.
  • Donia M; National Center for Cancer Immune Therapy, Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark; University of Copenhagen, Copenhagen, Denmark.
  • Faries MB; Department of Surgery, The Angeles Clinic, Cedars Sinai Medical Center, Los Angeles, USA.
  • Gaudy-Marqueste C; Department of Dermatology and Skin Cancer, Aix Marseille University, Hôpital Timone, Marseille, France.
  • Gogas H; First Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
  • Grob JJ; Department of Dermatology and Skin Cancer, Aix Marseille University, Hôpital Timone, Marseille, France.
  • Guckenberger M; Department of Radio-Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Haanen J; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hayes AJ; Department of Academic Surgery, Royal Marsden NHS Foundation Trust, London, UK.
  • Hoeller C; Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Lebbé C; AP-HP Dermatology, Université de Paris, Paris, France; INSERM U976, Hôpital Saint Louis, Paris, France.
  • Lugowska I; Early Phase Clinical Trials Unit, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Mandalà M; Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.
  • Márquez-Rodas I; Department of Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
  • Nathan P; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
  • Neyns B; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Olofsson Bagge R; Sahlgrenska Cancer Center, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden; Wallenberg Centre for Molecular and Translational M
  • Puig S; Dermatology Service, Hospital Clínic de Barcelona and University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August i Pi Sunyer, Barcelona, Spain; CIBERER, Instituto de Salud Carlos III, Barcelona, Spain.
  • Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Schilling B; Department of Dermatology, University Hospital Würzburg, Würzburg, Germany.
  • Sondak VK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa.
  • Tawbi H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Testori A; Department of Dermatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Keilholz U; Charité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Ann Oncol ; 31(11): 1449-1461, 2020 11.
Article em En | MEDLINE | ID: mdl-32763452
ABSTRACT
The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5-7 September 2019 in Amsterdam, The Netherlands. The conference included a multidisciplinary panel of 32 leading experts in the management of melanoma. The aim of the conference was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where available evidence is either limited or conflicting. The main topics identified for discussion were (i) the management of locoregional disease; (ii) targeted versus immunotherapies in the adjuvant setting; (iii) targeted versus immunotherapies for the first-line treatment of metastatic melanoma; (iv) when to stop immunotherapy or targeted therapy in the metastatic setting; and (v) systemic versus local treatment of brain metastases. The expert panel was divided into five working groups in order to each address questions relating to one of the five topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the results relating to the management of locoregional melanoma, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation. All participants approved the final manuscript.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article